Drugs /

hdac inhibitor cxd101

Back to Drugs List

Overview

NCI Definition [1]:
A novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Although the exact therapeutic mechanism of action for CXD101 is not known, oral administration of this agent should inhibit the catalytic activity of HDAC, which results in an accumulation of highly acetylated histones, followed by the induction of chromatin remodeling and an altered pattern of gene expression. HDAC, a family of enzymes upregulated in many tumor types, deacetylates chromatin-associated histone proteins.

Clinical Trials

View Clinical Trials for hdac inhibitor cxd101

Hdac inhibitor cxd101 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating hdac inhibitor cxd101, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open).

BCL2 Fusion, BCL6 Fusion, and EBV Positive are the most frequent biomarker inclusion criteria for hdac inhibitor cxd101 clinical trials.

Diffuse large B-cell lymphoma, diffuse large B-cell lymphoma, not otherwise specified, and double-hit lymphoma are the most common diseases being investigated in hdac inhibitor cxd101 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Hdac Inhibitor Cxd101
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Hdac Inhibitor Cxd101
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating hdac inhibitor cxd101 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
azd 9468, histone deacetylase inhibitor cxd101, hdac inhibitor cxd101, cxd101, azd9468, histone deacetylase inhibitor cxd101
Drug Target(s) [2]:
HDAC1, HDAC2, HDAC3
NCIT ID [1]:
C112177

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.